Lutetium Lu-177 Vipivotide Tetraxetan
A PSMA-targeted radioligand therapy approved for prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer. It delivers targeted radiation to prostate cancer cells by binding to PSMA, a protein highly expressed on prostate cancer cells.
Molekularmasse
1216,1000 g/mol
TPSA
374,00 Ų
Therapeutische Bereiche
Pharmacokinetics (PK)
Pharmacodynamics (PD)
2D-Struktur
Cite this structure
Embed this structure
SMILES
C1CC(CCC1CNC(=O)CN2CCN(CCN(CCN(CC2)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)N[C@@H](CC3=CC4=CC=CC=C4C=C3)C(=O)NCCCC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O.[177Lu+3]
InChI
InChI=1S/C49H71N9O16.Lu/c59-40(28-55-17-19-56(29-42(62)63)21-23-58(31-44(66)67)24-22-57(20-18-55)30-43(64)65)51-27-32-8-12-35(13-9-32)45(68)52-39(26-33-10-11-34-5-1-2-6-36(34)25-33)46(69)50-16-4-3-7-37(47(70)71)53-49(74)54-38(48(72)73)14-15-41(60)61;/h1-2,5-6,10-11,25,32,35,37-39H,3-4,7-9,12-24,26-31H2,(H,50,69)(H,51,59)(H,52,68)(H,60,61)(H,62,63)(H,64,65)(H,66,67)(H,70,71)(H,72,73)(H2,53,54,74);/q;+3/p-3/t32?,35?,37-,38-,39-;/m0./s1/i;1+2
Molecular Formula
C49H68LuN9O16
HBD / HBA
8 / 20
Rotierbare Bindungen
24
Schwere Atome
75
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
A PSMA-targeted radioligand therapy approved for prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer. It delivers targeted radiation to prostate cancer cells by binding to PSMA, a protein highly expressed on prostate cancer cells.
Yes, Lutetium Lu-177 Vipivotide Tetraxetan is an approved drug. It has reached clinical phase 4. It is classified as a Protein.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4594406. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 122706785. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="lutetium-lu-177-vipivotide-tetraxetan"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/lutetium-lu-177-vipivotide-tetraxetan/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/lutetium-lu-177-vipivotide-tetraxetan/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/lutetium-lu-177-vipivotide-tetraxetan/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="lutetium-lu-177-vipivotide-tetraxetan"></drugfyi-drug>